Opicapone Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 25 mg, 50 mg
Reference Brands: Ongentys (USA/EU)
Category:
Neurology
Opicapone is available in Capsules
and strengths such as 25 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Opicapone is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Opicapone can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Opicapone, marketed under the brand name Ongentys, is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor used as adjunctive therapy with levodopa in patients with Parkinson’s disease. It is specifically indicated for individuals experiencing “off” episodes, where the effects of levodopa wear off before the next dose, leading to a return of motor symptoms.
Opicapone works by inhibiting the COMT enzyme in the peripheral tissues, which is responsible for the breakdown of levodopa in the body. By blocking this enzyme outside the brain, opicapone enhances and prolongs the availability of levodopa, allowing more of it to reach the central nervous system where it is converted into dopamine. Importantly, opicapone does not inhibit COMT within the brain, contributing to its targeted peripheral action.
As a result of sustained levodopa levels, dopamine concentrations in brain regions responsible for movement and coordination are better maintained. This leads to improved control of Parkinson’s disease symptoms such as stiffness, slowness of movement, and reduced mobility. With its once-daily dosing and long-lasting COMT inhibition, opicapone provides a convenient and effective option for optimizing levodopa therapy in Parkinson’s disease management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing